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Abstract
Tendon and ligament injuries have always been complex to treat, with recovery 
often taking many months, if successful at all. This chapter looks at recent work 
undertaken using regenerative medicine, specifically gene therapy and the advances 
that have been made in equine therapy. It looks at the process from plasmid con-
struction, in vitro testing through to trialing the equine-specific plasmid construct 
in horses with superficial digital flexor tendon (tendinitis) and suspensory liga-
ment branch injuries. It also looks at the rationale for utilizing vascular endothelial 
growth factor (VEGF164) and a basic fibroblast growth factor (FGF2) for these 
trials and the cellular effects and potential mechanisms of actions.
Keywords: horse, gene therapy, tissue regeneration, superficial digital flexor tendon, 
tendon injuries, suspensory ligament
1. Introduction
Tendon and ligament injuries are the most common traumas in horses (Equus 
caballus) irrespective of the age and breed [1]. Based on the statistics, injuries in 
sport horses can achieve 86% of a total morbidity rate, with 37% of them account-
ing for muscle, tendon and ligament pathologies. As a rule, musculoskeletal injuries 
require long-term recovery for 9–12 months [2]. Tendon and ligament injuries result 
in a loss of performance of the horses and frequently cause discomfort or pain. 
Therefore, the animals are unable to participate in competitions for a long period 
of time. Complications of these injuries include chronic musculoskeletal diseases. 
They result in degenerative-dystrophic damage of collagen fibers of tendons as well 
as adjacent and underlying tissues. Incomplete tissue recovery leads to recurrent 
injuries in 80% of horses with treated tendon micro- and macroruptures within 
3–12 months after the first injury [3].
Methods of regenerative medicine are used for appropriate regeneration of 
damaged tissue in animals. These include the administration of stem cells [4, 5] 
and recombinant proteins, as well as gene therapy. These methods are presently the 
most advanced and promising approaches to manage musculoskeletal disorders [6]. 
However, regenerative medicine is mainly targeted toward the treatment of human 
disorders. Animals are mostly considered as models to test drugs and devices 
intended for human use. Drugs developed for human use can be ineffective for the 
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treatment of animal diseases due to partial homology of physiological processes. 
When given to animals, such products can cause long-term immunological disor-
ders, decrease the efficacy of a subsequent treatment or even cause adverse side 
effects including anaphylactic shock.
In a veterinary practice, an autologous graft rejection can be avoided in 85% of 
cases [7]. The likelihood of immune responses in animals to the administration of 
allogenic or autologous species-specific stem cells is also low [8–10]. However, full 
homology can be of vital importance when applying more advanced therapeutic 
approaches such as gene therapy.
Gene therapy is a novel, rapidly developing trend in regenerative medicine 
and veterinary, which can provide continuous stimulation of regeneration. When 
this approach is used, a recipient’s body constantly synthesizes its own substances 
instead of a multiple drug (pharmaceuticals, recombinant proteins and so on) 
delivery. Gene therapy has been successful in the treatment of various human 
disorders [11, 12], and it can be used to treat animals [13]. However, species-specific 
recombinant genes that would provide biological activity and at the same time have 
no immunological side effects should be developed for this purpose. A therapeutic 
potential of gene therapy for the treatment of tendinitis and desmitis in sport horses 
will be discussed in detail in this review, especially those related to a series of papers 
recently covering gene therapy in horses [14–17].
2.  Use of a species-specific plasmid construct in the treatment  
of traumas in horses
2.1 Description of the plasmid construct
A group of scientists from Russia and Great Britain developed and tested a drug 
for gene therapy of soft tissue injuries in horses. This gene construct is plasmid 
DNA (pDNA), encoding animal-specific genes (Figure 1). A plasmid construct 
pBUDK-ecVEGF164-ecFGF2 based on a pBudCE4.1 vector contained codon-opti-
mized sequences of horse genes, a vascular endothelial growth factor (VEGF164) 
and a basic fibroblast growth factor (FGF2) under eukaryotic promoters (EF-1α 
and CMV promoters, respectively) [14].
These genes were selected with good reason as VEGF stimulates synthesis of 
DNA and proliferation of cells involved in antiapoptotic signaling pathways. It 
promotes the proliferation and migration of endothelial cells, stimulates angio-
genesis and attracts endothelial progenitor cells from bone marrow, stimulates 
the activity of pericytes and stabilizes newly formed blood vessels. VEGF is also a 
Figure 1. 
Map of recombinant plasmid pBUDK-ecVEGF164-ecFGF2 [14].
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chemoattractant for smooth muscle cells, monocytes, macrophages and granulo-
cytes. All of these are involved in the process of wound healing. VEGF also increases 
vessel wall permeability at the site of injury that enhances the formation of granula-
tion tissue [14].
In turn, FGF2 exerts a wide range of mitogenic and angiogenic activities and is 
a neurotrophic factor. In intact tissues, it is present in a basement membrane of the 
epithelium and in the subendothelial extracellular matrix of blood vessels. It stimu-
lates cell proliferation, regeneration of nervous, muscle and connective tissues. 
Also, FGF2 activates de novo formation of blood vessels by triggering the process of 
angiogenesis [18].
Thus, a mechanism of action of gene therapy comprising VEGF and FGF2 is to 
stimulate synthesis of proteins in a recipient that enhances the vascularization of 
damaged tissues. This, in turn, leads to a higher regeneration rate. Both VEGF and 
FGF2 are well-known growth factors with a wide range of mitogenic and angiogenic 
activity. They also contribute to regeneration of muscle and connective tissues. 
What is more important is that in combination these factors demonstrate synergis-
tic effects that surpass those of therapy with just one growth factor [19].
This gene product has been tested for identification and functional activity in 
mammal cells in the laboratory. Full genetic sequencing and restriction analysis 
with subsequent agarose gel electrophoresis demonstrated a complete compliance 
with the claimed structure of pBUDK-ecVEGF164-ecFGF2 (Figure 2).
Biosynthesis of recombinant VEGF164 and FGF2 in transfected immortalized 
HEK293FT cells was confirmed by an immunofluorescence assay with anti-VEGF 
and anti-FGF2 antibodies (Figure 3), which confirmed co-expression of recombi-
nant proteins in transgenic cells [14, 14].
The biological activity of the рBUDK-ecVEGF164-ecFGF2 DNA plasmid was 
evaluated during in vitro experiments in horse stem cells. For this purpose, horse 
MSCs were isolated under a standard procedure by incubating a subcutaneous adi-
pose tissue homogenate with crab collagenase. The cells obtained were identified as 
MSCs with flow cytofluorometry-more than 80% of them expressed MSC-specific 
markers (Thy-1 in 99.8% and CD44 in 83% of the cells) and no CD34 or CD45 was 
Figure 2. 
Analysis of VEGF164 and FGF2 biosynthesis by immunoblotting in HEK293FT cells after transfection. 
Electrophoresis in 12% SDS-PAGE gel was performed in Laemmli system. Antibodies against human actin, 
VEGF and FGF2 were used. Bands correspond to human actin (42 kDa), horse VEGF164 (22.3 kDa) and 
horse FGF2 (17.2 kDa). M-molecular weight protein marker (GE LifeSciences RPN756E); Ec-HEK293FT cells 
transfected with pBUDK-ecVEGF164-ecFGF2; control nontransfected cells [14].
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expressed (data not provided). Thus, according to literature comparisons and based 
upon the laboratory data, the cells obtained were equine MSCs [20].
Genetic modification of horse MSCs with pDNA рBUDK-ecVEGF164-ecFGF2 
showed that transfected cells possess a higher ability to form a capillary-like 
networks on the Matrigel™ matrix as compared to intact cells (р < 0.005) 
(Figure 4).
2.2 Use of the plasmid construct in vivo
Due to a high incidence of tendon and ligament injuries in horses, a high rate of 
recurrent traumas and a prolonged period of recovery that normally lasts for several 
months and up to 15 months with severe injuries, these injuries are a medical and 
surgical challenge. Even when modern technologies are applied, in many cases, 
damaged tendons and ligaments demonstrate biochemical and ultrastructural 
abnormalities after 12 months and preinjury biomechanical properties are not 
completely restored [21].
A total of 12 horses were given gene therapy [15, 16] through in vivo trials of 
the treatment. Out of them, eight horses had naturally occurring injuries of the 
superficial digital flexor tendon (SDFT; tendinitis) and four horses had suspensory 
ligament branch (SLB) desmitis. All the horses had spontaneous SDFT and SLB 
injuries and were included into the study from 2015 to 2017 undergoing treatment 
in the veterinary clinic “New Century” at the Moscow State Academy of Veterinary 
and Biotechnologies, Moscow.
Figure 3. 
Immunofluorescence analysis of VEGF164 and FGF2 biosynthesis in HEK293FT cells, 48 h after transfection. 
(A) Negative control: HEK293FT cells without pDNA transfection, nuclei-stained DAPI (blue). (B)–(D) 
HEK293FT cells transfected with pBUDK-ecVEGF164-ecFGF2. b) Staining with primary antibody against 
VEGF and secondary antibody, conjugated with a fluorescent label Alexa Fluor 555 (red). (C) Staining with 
primary antibody against FGF2 and secondary antibody, conjugated with a fluorescent label Alexa Fluor 488 
(green). (D) Overlay image of a, c and d: VEGF (red), FGF2 (green), cell nuclei stained with DAPI (blue) 
[14].
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Gene therapy of the four horses with injured SLBs showed that before treatment 
all horses had pain in the injured leg. By day 40 after treatment, no animals had any 
sings of inflammation at the site of injury, nor was there a change in the skin surface 
temperature within the area of injury, swelling or tenderness when palpated. By day 
20 after treatment, lameness significantly reduced as compared to the baseline. By 
12 weeks and during subsequent follow-up examinations, no horses were lame.
Ultrasound parameters in damaged SLB began to improve 20 days after the 
onset of treatment, this positive tendency remaining thereafter. Parameters such 
as changes of the zone of damage, echogenicity and fiber alignment made this 
especially evident. When the treated horses started doing a program of physical 
exercise, the ligament architecture constantly improved, as indicated by their 
longitudinal alignment and length (Figure 5).
Based on the examination results, only one horse had no significant ultrasound 
improvements in the first 90 days after pDNA injection. On days 20 and 40, this 
horse had new hypoechoic lesions that indicate a nonstable healing process. By 
120–180 days after treatment, this horse had a noticeable ultrasound improvement 
in the site of injury.
Color Doppler ultrasonography (CDU) demonstrated evidently increased blood 
supply by day 20 after pDNA injection. This tendency remained up to day 40 and 
Figure 5. 
Ultrasound images prior to plasmid DNA encoding VEGF164 and FGF2 genes on day 0 (A), 20 (B), 40  
(C), 90 (D), 180 (E) and 300 (F) after administration in horse with SLB desmopathy. Arrows indicate lesion.
Figure 4. 
In vitro angiogenesis assay using Matrigel to characterize the proangiogenic effect mediated by genetic 
modification of  mesenchymal stem cells.
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was high until day 90. By day 180 after plasmid injection, CDU parameters reduced 
to baseline values in most horses (with the baseline set at values within an intact 
limb of the same animal). There was no significant correlation between the soft 
tissue damage severity prior to treatment and post-treatment CDU parameters.
Ultrasound parameters of SDFT lesions in most horses began to improve 20 days 
after treatment [15]. This positive tendency remained during the follow-up period. 
With the onset of training, healing of the damaged tissue increased in the tendon 
treated. This manifested as a longitudinal alignment of fibers and an increase in 
their length [16].
After treatment, the echogenicity of the damaged SDFT constantly and signifi-
cantly decreased from day 0 to day 60 in all horses except one. In 3 months after the 
beginning of treatment, the echostructure was more uniform in most horses, with 
collagen fibers arranged in parallel to the longitudinal axis.
A linear fiber pattern in horses with SDFT injuries also improved during the 
study, but this was happening more slowly when compared to the echogenicity. 
Within nine months, there were scarcely any signs of tendon damage in most of 
the horses with the SDFT injury. They had correct alignment and a well-arranged 
longitudinal pattern of fibers.
Doppler ultrasonography demonstrated a significant improvement in 
blood supply of the affected areas by day 20 [16]. This tendency continued for 
90–120 days, with a peak that was reached on day 40. After postinjection day 180, 
the vascularization decreased to baseline levels (as in healthy limbs of the same 
animal). There was no significant correlation between the injury severity before 
treatment and CDU parameters afterwards. There were no significant differences 
in CDU images between horses with SDFT and SLB injuries after treatment; CDU 
changes were strictly individual. CDU changes can be due to hypervascularity 
being natural in the process of healing. Normally, tendons and ligaments are 
hypovascular [22]. A short-term increase in blood flow results in response to 
damage-associated tissue hypoxia. We propose that the gene therapy enhanced this 
effect markedly.
To identify possible side effects, all horses were constantly examined by a veteri-
narian in the clinic from the time of plasmid administration until 12 months later. 
Horses did not have any side effects to the pDNA administration, and horse age, 
gender and the duration of lameness had no effect on the outcome of gene therapy. 
The main differences in clinical outcomes were determined by the extent and site of 
the animal’s soft tissue damage sustained before treatment. The study results showed 
that only one horse with a serious injury of the SLB and body did not respond to 
treatment, and it was lame for the first 3 months after the onset of therapy. Only one 
horse that recovered after gene therapy (initially with SDFT tendonitis) suffered a 
repeated injury at the same site 6 months after treatment [15, 16]. In the 12-month 
follow-up after treatment, owners of the other horses rated gene therapy results as 
good or excellent in terms of sporting success.
3. Discussion on the use of gene therapy in horses
One should emphasize that the disappearance of lameness with treated ten-
dinitis or desmitis in a horse does not mean absolute tissue regeneration. In these 
studies, rapid and mostly complete regeneration of both the tendon and ligament 
occurred within 2–3 months of treatment, which included a single injection of 
pBUDK-ecVEGF164-ecFGF2. This was confirmed by increased echogenicity and 
homogeneity at the site of injury, as well as an increased percentage of parallel 
collagen fibers.
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Thus, the study data are encouraging and demonstrated a positive effect of 
using pDNA encoding horse-specific proteins at early stages of healing of traumatic 
tendinitis and desmitis, when injected into the site of injury. In part, this can be 
explained by coincidence with conditions and stages of normal tendon healing. 
However, the horses included into the study had moderate or severe tendon injuries. 
It is well known that such injuries are associated with a poor prognosis in response 
to standard treatments.
A drawback of these clinical studies is that they did not identify an exact mecha-
nism of action of direct gene therapy with pBUDK-ecVEGF164-ecFGF2 on the 
regeneration of damaged horse tendons and ligaments. Since the horses had fully 
recovered, the investigators considered possible histological interventions to take 
tissue samples as inappropriate. If histological samples could be taken looking at the 
cell types, checking for inflammatory reactions and cells associated with inflam-
mation and immune responses would be advantageous for confirming the lack of 
immune response at a cellular level. In addition, investigating the healing mecha-
nism via histology by looking at collagen type and wound repair would further the 
knowledge in this area. Adding RNA and protein expression studies would also help 
understand the mechanisms involved in this therapy. The pDNA administration 
used also avoids possible side effects associated with vector-mediated insertional 
mutagenesis when integration into the patient’s genome is the long-term aim. This 
is not necessary in these disorders as long-term correction/replacement is not 
required. As previous reports of treatment results of such tendinitis and desmitis 
in horses are lacking, results of this gene therapy cannot be compared with those of 
other treatment methods.
Therefore, gene therapy, as one of the most advanced technologies in medicine, 
is a promising treatment for hereditary diseases and in addition offers new pos-
sibilities for a clinical management of numerous orthopedic disorders, including 
tendon and ligament injuries [23–25]. The use of direct gene therapy with species-
specific growth factors is quite promising for the treatment of orthopedic disorders 
not only in horses but also in other animal species and in people [17]. The successful 
use of direct gene therapy with a similar plasmid construct based on dog-specific 
VEGF164 genes and bone morphogenetic protein (BMP2) to treat an anterior 
cruciate ligament injury in large dogs has been previously reported [26]. Moreover, 
there is a case report on using gene therapy to treat patients with critical lower limb 
ischemia [27]. Finally, plasmid DNA pl-VEGF165 (approved as Neovasculgen), 
encoding human VEGF165, has demonstrated its safety and efficacy in the treat-
ment of atherosclerotic peripheral arterial disease in patients with chronic lower 
limb ischemia without side effects [28]. The high efficacy and safety of direct gene 
therapy have been demonstrated in all of these cases. There are also numerous ben-
efits of using pDNA rather than recombinant viruses. Plasmids are relatively easy to 
construct, can be produced in large quantities and provide a safe method of delivery 
with low levels of immunogenicity associated with delivery. They can often be kept 
at room temperature for long periods of time, which is especially useful in clinical 
settings. Although they have lower levels of gene transfer, the studies carried out in 
the horse show that delivery is appropriate and efficient in these circumstances as it 
was delivered directly to the injured area.
VEGF and FGF2 gene therapy’s direct effects on the regeneration of tendon and 
ligament injuries in horses should be further evaluated in a larger number of experi-
mental animals, for a longer follow-up period and in a randomized controlled clini-
cal study. Complete and more detailed results could also be obtained by histological 
examination and immunohistochemistry of samples and biopsy materials given the 
right conditions. Factors such as gene expression levels in tissues, collagen analysis, 
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proteins and further studies of pathological biochemistry will help identify the 
main mechanisms of action.
4. Conclusions
The introduction of gene therapy in veterinary clinics becomes ever more pos-
sible; however, there are issues that require solutions. The future of veterinary gene 
therapy seems promising thanks to the studies described, and many other therapies 
are likely to be approved for use in both human and animal medicine [17].
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